检索结果-南通市图书馆

Anlotinib in combination with Envolizumab plus Etoposide for the treatment of EX-SCLC:a case report

Clinical Research Communications 2024年第1期7卷 29-33页

作者： Hong-Lei Guo Hong Wang Yan-Qi Song Xin-Long Song Ai-Di Wang Bao-Shan Liu Graduate School Tianjin University of Traditional Chinese MedicineTianjin 301617China Department of Chinese Medicine Tianjin Medical University General HospitalTianjin 300052China

Background:Small cell lung cancer(SCLC)is an aggressive malignant tumor with strong immunosuppressive effects,characterized by rapid doubling time and poor prognosis.Currently,effective therapeutic options are urgently needed for Extensive-stage small-cell lung Cancer.Case description:In the present case,a combination therapy of anlotinib,envolizumab,and etoposide was administered to treat an 80-year-old female patient with extensive-stage SCLC accompanied by mediastinal lymph node and bone metastasis.After two cycles of treatment,the tumor lesions in the right lungs decreased from 5.04*3.44 cm to 1.65*1.42 cm.As of now,no significant mass is seen there and no serious adverse reactions in this patient.Until September 2023,she has survived for 18 months with no disease progression.Conclusions:Research shows that Alectinib,in combination with evolocumab plus etoposide,could be an original,viable therapeutic option for the treatment option of patients with extensive-stage SCLC.

关键词： Extensive-stage Small Cell Lung Cancer anti-angiogenesis pd-1 inhibitors Combined treatment case report

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The Progress of pd-1 inhibitors in Small-Cell Lung Cancer

The Progress of PD-1 Inhibitors in Small-Cell Lung Cancer

引用

浙江省免疫学会第六次会员代表大会暨第十一次学术大会

作者： Mengyuan Yang Ying Yuan Hong Shen DepartmentofMedicalOncology theSecondAffiliatedHospitalZhejiangUniversitySchoolofMedicine

Recently,the immune checkpoint inhibitors have shown significant clinical responses in a variety of malignancies,including melanoma,non-small-cell lung cancer(NSCLC)and renal carcinoma etc.Despite num

关键词： small-cell lung cancer pd-1 inhibitors animal experiments clinical trials

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

pd-1 inhibitor in combination with fruquintinib therapy for initial unresectable colorectal cancer:A case report

引用

World Journal of Clinical Cases 2022年第14期10卷 4669-4675页

作者： Hong-Qiang Zhang Chang-Zhi Huang Jing-Yu Wu Zhen-Ling Wang Yu Shao Zan Fu Department of General Surgery The First Affiliated Hospital of Nanjing Medical UniversityNanjing 210029Jiangsu ProvinceChina

BACKGROUND pd-1 inhibitors in combination with fruquintinib have not previously been reported as neoadjuvant therapy for patients with colorectal cancer.In this case report,the combination of a pd-1 inhibitor and fruquintinib demonstrated good efficacy in patients with MSI-H colorectal cancer.CASE SUMMARY The patient was a young man in his 30s who had MSI-H type colon cancer.The patient underwent four cycles of neoadjuvant therapy with a pd-1 inhibitor combined with fruquintinib before surgery,resulting in regression of the mass and a successful surgery.CONCLUSION Some patients with colorectal cancer have the MSI-H type,and the first-line chemotherapy regimen is not effective.However,pd-1 monoclonal antibody immunotherapy has a good therapeutic effect,which can be improved by combination therapy with fruquintinib.We recommend that patients with a history of colon or rectal cancer receive universal MSI testing;then,neoadjuvant therapy should be used.

关键词： Colorectal cancer Neoadjuvant pd-1 inhibitors Fruquintinib MSI-H Case report

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Sarcomatoid Intrahepatic Cholangiocarcinoma After Immunotherapy:A Case Report and Review of the Literature

引用

Journal of Clinical and Translational Hepatology 2022年第6期10卷 1240-1249页

作者： Zheng Zeng Yu Liu Jing Yu Qiang Xu Yong Wang Chang Zhao Ou Jiang Department of Abdominal Oncology The Second People’s Hospital of NeijiangNeijiangSichuanChina Department of Pathology The Second People’s Hospital of NeijiangNeijiangSichuanChina

Sarcomatoid carcinoma is a rare tumor that is composed of a mixture of malignant epithelial cells and mesenchymal cells.Many studies have reported that sarcomatoid carci-noma occurs in multiple organs including the liver.Sarco-matoid intrahepatic cholangiocarcinoma(S-iCCA)is an ex-tremely rare tumor that primarily occurs in the liver.This case occurred in a middle-aged man who was admitted to our hospital with abdominal pain.Enhanced computed to-mography of the abdomen showed a low-density mass in the upper right posterior lobe of the liver with enhancement in the periphery.Histological and immunohistochemical examination indicated that the tumor was malignant,with both cancer and sarcoma components,and was positive for cytokeratin and vimentin.The patient was diagnosed with S-iCCA.Metastases appeared in the liver and lung 4 months after surgery.Two cycles of chemotherapy were adminis-tered.Because of enlargement of the tumor,anti-angiogen-ic agents combined with immunotherapy were subsequently given to achieve disease control.To the best of our knowl-edge,this is the first reported case of a programmed cell death-1 inhibitor used in a S-iCCA patient.The purpose of this case report and literature review is to enhance clinician understanding of S-iCCA and to explore safe and effective treatment methods.

关键词： Sarcomatoid intrahepatic cholangiocarcinoma Sarcomatoid degen-eration pd-1 inhibitors Anti-angiogenic therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：